Abivax Stock: Shares Break Through Resistance Boosted by Promising Clinical Data

Impact of Clinical Data on Abivax's Stock Performance

Abivax's stock price directly benefited from the scientific communication revealed at the European Congress of Gastroenterology. The biopharmaceutical company presented the first evidence of anti-fibrotic activity of obefazimod, its main therapeutic candidate for the treatment of chronic inflammatory bowel diseases. New analyses on the clinical efficacy and tolerance profile of the compound were also communicated on this occasion. This publication comes one month before the announcement of the annual results for 2025, scheduled for March 23. The biotech's stock performance remains spectacular over one year, with a gain of 1,378%, reflecting the advancement of its clinical pipeline and milestones achieved in recent quarters. Over three months, the stock has risen by nearly 10%, confirming a steady trend.

Technical Analysis of Today's Trading Session

From a graphical perspective, today's session is particularly significant. The price of 112.80 euros surpasses the resistance identified at 112.40 euros, a level that had contained previous attempts to advance. This breakthrough occurs while the stock is significantly above its 50-day moving average, located at 105.04 euros, indicating a solidly anchored upward trend in the medium term. The gap with the 200-day moving average, positioned at 66.62 euros, illustrates the magnitude of the movement initiated over the past year. However, the RSI, a momentum indicator measuring the speed and magnitude of price variations, reaches 78, a level considered overbought beyond the usual threshold of 70. This configuration signals that the stock has experienced a rapid acceleration and that buyers have dominated recent trading. In case of a pullback, the most relevant technical support is at 93.70 euros. The monthly volatility remains contained at 11.79%, while the beta of 0.14 indicates a very low correlation with general market movements.